Cargando…

Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents

Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times....

Descripción completa

Detalles Bibliográficos
Autores principales: Sflakidou, Eleni, Leonidis, George, Foroglou, Eirini, Siokatas, Christos, Sarli, Vasiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572494/
https://www.ncbi.nlm.nih.gov/pubmed/36235168
http://dx.doi.org/10.3390/molecules27196632
_version_ 1784810628974641152
author Sflakidou, Eleni
Leonidis, George
Foroglou, Eirini
Siokatas, Christos
Sarli, Vasiliki
author_facet Sflakidou, Eleni
Leonidis, George
Foroglou, Eirini
Siokatas, Christos
Sarli, Vasiliki
author_sort Sflakidou, Eleni
collection PubMed
description Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times. Although natural compounds and their derivatives have demonstrated strong antitumor activity in many types of cancer, their poor pharmacokinetic properties, low cell selectivity, limited bioavailability and restricted efficacy against drug-resistant cancer cells hinder their wide clinical application. Conjugation of natural products with other bioactive molecules has given rise to a new field in drug discovery resulting to the development of novel, bifunctional and more potent drugs for cancer therapy to overcome the current drawbacks. This review discusses multiple categories of such bifunctional conjugates and highlights recent trends and advances in the development of natural product hybrids. Among them, ADCs, PDCs, ApDCs, PROTACs and AUTOTACs represent emerging therapeutic agents against cancer.
format Online
Article
Text
id pubmed-9572494
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95724942022-10-17 Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents Sflakidou, Eleni Leonidis, George Foroglou, Eirini Siokatas, Christos Sarli, Vasiliki Molecules Review Cancer is one of the top leading causes of death worldwide. It is a heterogenous disease characterized by unregulated cell proliferation and invasiveness of abnormal cells. For the treatment of cancer, natural products have been widely used as a source of therapeutic ingredients since ancient times. Although natural compounds and their derivatives have demonstrated strong antitumor activity in many types of cancer, their poor pharmacokinetic properties, low cell selectivity, limited bioavailability and restricted efficacy against drug-resistant cancer cells hinder their wide clinical application. Conjugation of natural products with other bioactive molecules has given rise to a new field in drug discovery resulting to the development of novel, bifunctional and more potent drugs for cancer therapy to overcome the current drawbacks. This review discusses multiple categories of such bifunctional conjugates and highlights recent trends and advances in the development of natural product hybrids. Among them, ADCs, PDCs, ApDCs, PROTACs and AUTOTACs represent emerging therapeutic agents against cancer. MDPI 2022-10-06 /pmc/articles/PMC9572494/ /pubmed/36235168 http://dx.doi.org/10.3390/molecules27196632 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sflakidou, Eleni
Leonidis, George
Foroglou, Eirini
Siokatas, Christos
Sarli, Vasiliki
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
title Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
title_full Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
title_fullStr Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
title_full_unstemmed Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
title_short Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
title_sort recent advances in natural product-based hybrids as anti-cancer agents
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572494/
https://www.ncbi.nlm.nih.gov/pubmed/36235168
http://dx.doi.org/10.3390/molecules27196632
work_keys_str_mv AT sflakidoueleni recentadvancesinnaturalproductbasedhybridsasanticanceragents
AT leonidisgeorge recentadvancesinnaturalproductbasedhybridsasanticanceragents
AT forogloueirini recentadvancesinnaturalproductbasedhybridsasanticanceragents
AT siokataschristos recentadvancesinnaturalproductbasedhybridsasanticanceragents
AT sarlivasiliki recentadvancesinnaturalproductbasedhybridsasanticanceragents